Audrito and colleagues have recently reported that SIRT1 inhibition with nicotinamide has cytotoxic activity on B-CLL cells, and that this effect requires the presence of wild type p53 [13]. The gene discussed is SIRT1; the disease is B-cell chronic lymphocytic leukemia.